POSTERS ASCO 2024

Cáncer gastrointestinal

Colorrectal y anal

A phase II open‐label study with atezolizumab (atezo) in combination with bevacizumab (bev) in patients (pts) with advanced chemotherapy-resistant colorectal cancer (CRC) and MSI‐like molecular signature: The MoTriColor Consortium CT3 study.

A phase II open‐label study with atezolizumab (atezo) in combination with bevacizumab (bev) in patients (pts) with advanced chemotherapy-resistant colorectal cancer (CRC) and MSI‐like molecular signature: The MoTriColor Consortium CT3 study.

Abstract: 3589 Poster Bd #: 252

Poster

Descargar

Autor
Elena Élez, MD, PhD

Vall d’Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital

Una iniciativa científica de:

eco clover

Con el patrocinio de:

REGENERON